Reported Earlier, Actinium To Present Improved Survival Outcomes In TP53 Positive Patients At The EHA 2024 and Long-Term Efficacy Results In Older Patients Receiving An Iomab-B Led Bone Marrow Transplant In The Phase 3 SIERRA Trial
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals will present improved survival outcomes for TP53 positive patients and long-term efficacy results for older patients receiving Iomab-B led bone marrow transplants at the EHA 2024. The Phase 3 SIERRA trial showed a significant increase in median overall survival for TP53 mutation patients receiving Iomab-B.
May 15, 2024 | 7:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals will present significant survival outcomes for TP53 positive patients and long-term efficacy results for older patients at EHA 2024. The Phase 3 SIERRA trial showed a median overall survival of 5.49 months for TP53 mutation patients receiving Iomab-B, compared to 1.66 months for those who did not.
The significant improvement in survival outcomes for TP53 positive patients and long-term efficacy results in older patients receiving Iomab-B in the Phase 3 SIERRA trial is likely to positively impact Actinium Pharmaceuticals' stock price. The presentation at EHA 2024 will bring further attention to these promising results.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100